{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:20:46Z","timestamp":1787779246262,"version":"build-2784847793"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.alit.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:50:43Z","timestamp":1787777443000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["UNITE\u00ae Technology: Translating lysosomal targeting vaccines for allergy therapy"],"prefix":"10.1016","author":[{"given":"Wei","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri","family":"Heiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2026.07.009_bib1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/all.15807","article-title":"Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"78","author":"Shin","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2026.07.009_bib2","series-title":"Textbook of pediatric allergy","first-page":"1","article-title":"Epidemiology of allergic diseases","author":"Tripodi","year":"2024"},{"key":"10.1016\/j.alit.2026.07.009_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102569","article-title":"Novel approaches to prevent or cure allergic diseases","volume":"95","author":"Zadoo","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.alit.2026.07.009_bib4","first-page":"27","article-title":"Omalizumab: a monoclonal Anti-IgE antibody","volume":"7","author":"Belliveau","year":"2005","journal-title":"Medscape Gen Med"},{"key":"10.1016\/j.alit.2026.07.009_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4857869","article-title":"CryJ-LAMP DNA vaccines for Japanese red cedar allergy induce robust Th1-Type immune responses in Murine model","volume":"2016","author":"Su","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.alit.2026.07.009_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.33545\/26648865.2023.v5.i1a.26","article-title":"Exploring immunopathological mechanisms underlying allergic diseases: a comprehensive review","volume":"5","author":"Johnson","year":"2023","journal-title":"Int J Immunol Res"},{"key":"10.1016\/j.alit.2026.07.009_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202249978","article-title":"Pathogenic and nonpathogenic antibody responses in allergic diseases","volume":"55","author":"Ehlers","year":"2025","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.alit.2026.07.009_bib8","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1111\/all.14908","article-title":"The role of allergen-specific IgE, IgG and IgA in allergic disease","volume":"76","author":"Shamji","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2026.07.009_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612725","article-title":"Thymic stromal lymphopoietin (TSLP), its isoforms and the interplay with the epithelium in allergy and asthma","volume":"24","author":"Smolinska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.alit.2026.07.009_bib10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3389\/fimmu.2019.00821","article-title":"Mast cells and their progenitors in allergic asthma","volume":"10","author":"M\u00e9ndez-Enr\u00edquez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2026.07.009_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11882-018-0786-6","article-title":"Mast cell interactions and crosstalk in regulating allergic inflammation","volume":"18","author":"Velez","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.alit.2026.07.009_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.jaip.2025.05.030","article-title":"New advances in asthma care: improving management and outcomes","volume":"13","author":"Larenas-Linnemann","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2026.07.009_bib13","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jaip.2024.03.023","article-title":"Current management of allergic rhinitis","volume":"12","author":"Klimek","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2026.07.009_bib14","doi-asserted-by":"crossref","first-page":"8671","DOI":"10.1074\/jbc.272.13.8671","article-title":"The enhanced immune response to the HIV gp160\/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway","volume":"272","author":"Ruff","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.alit.2026.07.009_bib15","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.4049\/jimmunol.155.4.1818","article-title":"Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal\/lysosomal compartment enhances its presentation to MHC class II-restricted T cells","volume":"155","author":"Rowell","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.alit.2026.07.009_bib16","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.4049\/jimmunol.177.4.2265","article-title":"Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag Chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes","volume":"177","author":"Arruda","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.alit.2026.07.009_bib17","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1182\/blood-2010-02-268425","article-title":"Targeting of DEC-205 on human dendritic cells results in efficient MHC class II\u2013restricted antigen presentation","volume":"116","author":"Birkholz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.alit.2026.07.009_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nri3582","article-title":"The function of Fc\u03b3 receptors in dendritic cells and macrophages","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.alit.2026.07.009_bib19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1083\/jcb.117.2.311","article-title":"Transport of the lysosomal membrane glycoprotein lgp120 (lgp-A) to lysosomes does not require appearance on the plasma membrane","volume":"117","author":"Harter","year":"1992","journal-title":"J Cell Biol"},{"key":"10.1016\/j.alit.2026.07.009_bib20","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1002\/j.1460-2075.1996.tb00908.x","article-title":"The tyrosine-based lysosomal targeting signal in lamp-1 mediates sorting into Golgi-derived clathrin-coated vesicles","volume":"15","author":"H\u00f6ning","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.alit.2026.07.009_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000258","article-title":"HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.alit.2026.07.009_bib22","article-title":"LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition","volume":"14","author":"Rosean","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2026.07.009_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.850546","article-title":"Development and characterization of an HCMV multi-antigen therapeutic vaccine for glioblastoma using the UNITE platform","volume":"12","author":"Adhikari","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.alit.2026.07.009_bib24","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1080\/21645515.2017.1329070","article-title":"Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: a phase I study","volume":"13","author":"Su","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.alit.2026.07.009_bib25","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.alit.2026.07.009_bib26","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.addr.2008.02.002","article-title":"Forward genetic analysis of TLR-signaling pathways: an evaluation","volume":"60","author":"Hoebe","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.alit.2026.07.009_bib27","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-Mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design","volume":"198","author":"Pepini","year":"2017","journal-title":"J Immunol"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893026000936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893026000936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:50:47Z","timestamp":1787777447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893026000936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"alternative-id":["S1323893026000936"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2026.07.009","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UNITE\u00ae Technology: Translating lysosomal targeting vaccines for allergy therapy","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Allergology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}